Silver Book Fact

Macugen to treat wet age-related macular degeneration (AMD)

A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.

Gragoudas EA, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for Neovascular Age-Related Macular Degeneration. NEJM. 2004; 351(27): 2805-16. http://content.nejm.org/cgi/content/abstract/351/27/2805

Reference

Title
Pegaptanib for Neovascular Age-Related Macular Degeneration
Publication
NEJM
Publication Date
2004
Authors
Gragoudas EA, Adamis AP, Cunningham ET, Feinsod M, Guyer DR
Volume & Issue
Volume 351, Issue 27
Pages
2805-16
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but…  
  • Prescription eye drops could delay or prevent half of glaucoma cases in African Americans.  
  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.  
  • Women taking vitamins B6 and B12 and folic acid–as compared to women not taking these supplements–were found to have a 34% lower risk of age-related macular degeneration (AMD) and a…  
  • In general, every 10 mmHg reduction in systolic blood pressure reduces the risk of diabetes complications by 12%.